J.P. Morgan Securities LLC Xeris Pharmaceuticals Inc Amend 8.3 (3688E)
06 Julio 2021 - 12:12PM
UK Regulatory
TIDM0A8E
RNS Number : 3688E
J.P. Morgan Securities LLC
06 July 2021
Ap19
AMENDMENT
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing J.P. Morgan Securities
(Note 1) LLC
Company dealt in Xeris Pharmaceuticals,
Inc.
======================
Class of relevant security $0.001 common stock
to which the dealings
being disclosed relate
(Note 2)
======================
Date of dealing 22 June 2021
======================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities 3,506,083 5.28 976,610 1.47
----------------- -------------------
(2) Derivatives (other
than options) 401,188 0.60
----------------- -------------------
(3) Options and agreements
to purchase/sell
----------------- -------------------
Total 3,907,271 5.88 976,610 1.47
----------------- -------------------
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(USD)
(Note 5)
Purchase (Loan 11,500 N/A
Return)
1,467 3.9300 USD
Purchases 788 3.8800 USD
Purchases 1,903 3.8607 USD
Purchases 25,277 3.8592 USD
Purchases 13,385 3.8588 USD
Purchases 2,018 3.8580 USD
Purchases 100 3.8400 USD
Purchases 4,800 3.8325 USD
Purchases 816 3.8079 USD
Purchases
100 3.9100 USD
Sales 100 3.8700 USD
Sales 100 3.8600 USD
Sales 25,277 3.8592 USD
Sales 100 3.8300 USD
Sales 64 3.8200 USD
Sales 37 3.8197 USD
Sales 199 3.8100 USD
Sales 100 3.8000 USD
Sales
====================================== ====================
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant Price per
e.g. CFD (Note 6) securities unit
(Note 7) (USD) (Note
5)
Equity Swap Decrease Long 25,277 3.8592 USD
===================== ================== =============
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any
other person relating to the voting rights of any relevant
securities under any option referred to on this
form or relating to the voting rights or future acquisition or
disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 06 July 2021
Contact name Alwyn Basch
=============
Telephone number 0207 742 7407
=============
If a connected EFM, name N/A
of offeree/offeror with
which connected
=============
If a connected EFM, state N/A
nature of connection (Note
10)
=============
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEDKABDOBKDKOK
(END) Dow Jones Newswires
July 06, 2021 13:12 ET (17:12 GMT)
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Xeris Biopharma (LSE:0A8E)
Gráfica de Acción Histórica
De May 2023 a May 2024
